HER2 ADCs direct drug delivery to HER2-expressing cancer cells while limiting exposure to normal tissue.39 The currently available ADCs for HER2-positive cancer include trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd). Here, ERBB2 is linked to cancer.